JP2018508589A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508589A5
JP2018508589A5 JP2017568016A JP2017568016A JP2018508589A5 JP 2018508589 A5 JP2018508589 A5 JP 2018508589A5 JP 2017568016 A JP2017568016 A JP 2017568016A JP 2017568016 A JP2017568016 A JP 2017568016A JP 2018508589 A5 JP2018508589 A5 JP 2018508589A5
Authority
JP
Japan
Prior art keywords
bladder cancer
individual
composition according
liposome composition
mitomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017568016A
Other languages
English (en)
Japanese (ja)
Other versions
JP6859275B2 (ja
JP2018508589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/022909 external-priority patent/WO2016149516A1/en
Publication of JP2018508589A publication Critical patent/JP2018508589A/ja
Publication of JP2018508589A5 publication Critical patent/JP2018508589A5/ja
Application granted granted Critical
Publication of JP6859275B2 publication Critical patent/JP6859275B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017568016A 2015-03-17 2016-03-17 膀胱がんの治療方法 Expired - Fee Related JP6859275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134328P 2015-03-17 2015-03-17
US62/134,328 2015-03-17
PCT/US2016/022909 WO2016149516A1 (en) 2015-03-17 2016-03-17 Methods for the treatment of bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020188037A Division JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Publications (3)

Publication Number Publication Date
JP2018508589A JP2018508589A (ja) 2018-03-29
JP2018508589A5 true JP2018508589A5 (https=) 2019-04-25
JP6859275B2 JP6859275B2 (ja) 2021-04-14

Family

ID=56919480

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568016A Expired - Fee Related JP6859275B2 (ja) 2015-03-17 2016-03-17 膀胱がんの治療方法
JP2020188037A Withdrawn JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020188037A Withdrawn JP2021035973A (ja) 2015-03-17 2020-11-11 膀胱がんの治療方法

Country Status (5)

Country Link
US (1) US20180071253A1 (https=)
EP (1) EP3270898B1 (https=)
JP (2) JP6859275B2 (https=)
AU (1) AU2016233143B2 (https=)
WO (1) WO2016149516A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020207026A1 (en) * 2019-01-11 2021-07-29 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin C and method of manufacture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
KR100669053B1 (ko) 1999-04-23 2007-01-15 알자 코포레이션 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트
WO2003097647A1 (en) * 2002-05-15 2003-11-27 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2015191563A1 (en) * 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination chemotherapy comprising a liposomal prodrug of mitomycin c

Similar Documents

Publication Publication Date Title
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
WO2015048689A8 (en) Inhibitors of bruton's tyrosine kinase
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
WO2015191934A3 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CO6612185A2 (es) Composiciones famacéuticas para el tratamiento del cáncer y otras enfermedades o transtornos
WO2015114166A3 (en) Targeted drug conjugates
JP2016512817A5 (https=)
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2012097264A3 (en) Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
PH12018502422A1 (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
HK1245086A1 (zh) 处方药物组成及其制备和使用
MX376783B (es) Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos